Interaction Color Code
Clinical Bottom Line
Minimal data to guide interaction: weigh risks and benefits of using this combination
Drug 1
Drug 1 dose
150 mg elvitegravir / 150 mg cobicistat once daily
Drug 1 effect
Cmax decreased 12%, AUC increased 2%, Cmin increased 36%
Drug 2
Drug 2 dose
90 / 400 mg once daily
Drug 2 effect
Ledipasvir Cmax increased 63%, AUC increased 78%, Cmin increased 91%; Sofosbuvir Cmax increased 33%, AUC increased 36%; Sofosbuvir metabolite Cmax increased 33%, AUC increased 44%, Cmin increased 53%
Clinical Effects
Potential increase in ledipasvir toxicity
Management
Manufacturer does not recommend co-administration of ledipasvir / sofosbuvir with Stribild due to interaction with tenofovir disoproxil fumarate. If coadministering, monitor for tenofovir renal toxicity. May coadminister with Genvoya.
Import ID
142
